Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral CDK7 Inhibitor, at EORTC-NCI-AACR Meeting

Posted 2020-10-24, Public Technologies

October 24, 2020

Early Dose-Escalation Data Demonstrate Proof of Mechanism and Support Ongoing Development of SY-5609 for Difficult-to-Treat Cancers

On Track to Report Additional Data, including Clinical Activity Data, in Mid-2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals

Read Full Article

Popular News Stories

Melania yanks her hand out of Donald’s after presidential debate

Metro UK

Boris Johnson condemned for ‘appalling’ Tory alliance with neo-Nazi and anti-Muslim parties across Europe

The Independent

As election day nears, what final dirty tricks could Trump turn to?

The Guardian

Trump suggests Egypt may ‘blow up’ Ethiopia dam

Gulf News

Man found with van carrying guns and explosives planned Joe Biden assassination, court records say

Democratic Underground

New World Disorder: will a US-China cold war and Covid-19 finally kill off the United Nations?

South China Morning Post

UK ‘has launched clandestine attacks on Russia’, former national security chief claims

The Independent

China will focus on self-reliance and cutting financial risk, says Vice-President Wang Qishan

South China Morning Post

Nigeria protests: 69 people killed in unrest, President Buhari says

The National

Bolivian ex-president Morales leaves Argentina on flight to Venezuela

The Times of India

Osiris-Rex: Nasa probe risks losing asteroid sample after door jams

BBC News

China Calls Russia's Talk of Possible Military Alliance 'Positive,' with 'No Limit' to Their Ties

Newsweek

Overstuffed Nasa spacecraft Osiris-Rex losing particles after bingeing on Bennu

The Guardian

Seven bodies found in fertilizer shipment from Serbia to Paraguay

Irish Independent

Bolivia confirms Arce presidential election win

Manila Bulletin

Related News

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan Revocan is designed to...

Public Technologies 2020-10-21

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical...

Public Technologies 2020-10-22

Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot ...

Interimdata on first 19 patientsreleased in ASTRO Annual Meeting late-breaker presentation abstractshowedimprovement in overall survivaland multipleanti-cancer efficacy...

Tyler Morning Telegraph 2020-10-23

First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca

First patient dosed in monalizumab Phase 3 clinical trial triggers $50M payment from AstraZeneca 23 Oct 2020 07:00 CEST Company Name INNATE PHARMA ISN FR0010331421 Market...

Public Technologies 2020-10-23

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial ...

MALVERN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and...

Tyler Morning Telegraph 2020-10-22

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer

Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer October 22,...

Public Technologies 2020-10-22

SEC Filing (6-K) - Current Report by Foreign Issuer

EdgarFiling EXHIBIT 99.1 First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca Milestone payment further bolsters Innate's cash...

Public Technologies 2020-10-23

Related News